M 063
Alternative Names: Lenti-LAMN-S1S3; M-063Latest Information Update: 12 Apr 2023
Price :
$50 *
At a glance
- Originator M6P Therapeutics
- Class Gene therapies
- Mechanism of Action Alpha-mannosidase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Alpha-Mannosidosis